论文信息 - Proactive TDM for Crohn's disease patients in clinical remission under anti-TNF treatment: current state of evidence. - 字舞流文

Proactive TDM for Crohn's disease patients in clinical remission under anti-TNF treatment: current state of evidence.

S. Bonovas | G. Fiorino | J. Torres

[1] L. Stassen,et al. ECCO Guidelines on Therapeutics in Crohn's Disease: Surgical Treatment. , 2019, Journal of Crohn's & colitis.

[2] L. Stassen,et al. ECCO Guidelines on Therapeutics in Crohn's Disease: medical treatment. , 2019, Journal of Crohn's & colitis.

[3] B. Weiss,et al. Proactive Monitoring of Adalimumab Trough Concentration Associated With Increased Clinical Remission in Children with Crohn's Disease Compared with Reactive Monitoring. , 2019, Gastroenterology.

[4] D. Franchimont,et al. Increasing Infliximab Dose Based on Symptoms, Biomarkers, and Serum Drug Concentrations Does Not Increase Clinical, Endoscopic, and Corticosteroid-Free Remission in Patients With Active Luminal Crohn's Disease. , 2018, Gastroenterology.

[5] K. Van Steen,et al. Trough concentrations of infliximab guide dosing for patients with inflammatory bowel disease. , 2015, Gastroenterology.